Simons L A, Parfitt A, Simons J, Balasubramaniam S
University of NSW, Australia.
Aust N Z J Med. 1990 Oct;20(5):689-94. doi: 10.1111/j.1445-5994.1990.tb00400.x.
Clinical trials were conducted to assess the utility of HimegaR in the management of hyperlipidaemia. Himega is an ethyl ester concentrate from fish oil containing at least 50% n-3 fatty acid and minimal cholesterol. In Study 1, 13 subjects with primary hypertriglyceridaemia consumed Himega or a triglyceride-based fish oil in a randomised, double-blind crossover study for 12 weeks. Nine subjects took 2 g/day of n-3 fatty acid but four subjects with marked hypertriglyceridaemia took 4 g/day. Plasma triglycerides were reduced by approximately 50% with either product. There was a very similar effect on all lipid and lipoprotein parameters, including an 18% increase in LDL cholesterol and 23% increase in serum apolipoprotein B. In Study 2, nine subjects with primary hypercholesterolaemia took 2 g/day of n-3 fatty acid (Himega) or placebo (olive oil) in a randomised, double-blind crossover study for nine weeks. Plasma cholesterol was reduced by 6%, without significant change in LDL cholesterol. Fish oils in the form of ethyl esters or triglyceride are assimilated to a similar degree and lead to equivalent triglyceride-lowering in hypertriglyceridaemia, while simultaneously increasing LDL particle numbers. Himega does not reduce LDL levels in hypercholesteraemia, despite being a product with minimal cholesterol content.
开展了临床试验以评估HimegaR在治疗高脂血症中的效用。Himega是一种来自鱼油的乙酯浓缩物，含有至少50%的n-3脂肪酸且胆固醇含量极低。在研究1中，13名原发性高甘油三酯血症患者在一项随机、双盲交叉研究中服用Himega或基于甘油三酯的鱼油，为期12周。9名受试者每天服用2克n-3脂肪酸，但4名严重高甘油三酯血症患者每天服用4克。两种产品均可使血浆甘油三酯降低约50%。对所有脂质和脂蛋白参数的影响非常相似，包括低密度脂蛋白胆固醇增加18%和血清载脂蛋白B增加23%。在研究2中，9名原发性高胆固醇血症患者在一项随机、双盲交叉研究中，服用2克/天的n-3脂肪酸（Himega）或安慰剂（橄榄油），为期9周。血浆胆固醇降低了6%，低密度脂蛋白胆固醇无显著变化。乙酯形式或甘油三酯形式的鱼油吸收程度相似，在高甘油三酯血症中降低甘油三酯的效果相当，同时增加低密度脂蛋白颗粒数量。尽管Himega是一种胆固醇含量极低的产品，但它并不能降低高胆固醇血症患者的低密度脂蛋白水平。
